Caris Life Sciences, Inc. Balance Sheet
CAI / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
Caris Life Sciences, Inc. had $1.1B in total assets and $577M in shareholders' equity as of FY2025. Total debt was $378M against $796M in cash, resulting in a $418M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash & Equivalents | $796.3M | - | - |
| Accounts Receivable | $112.1M | - | - |
| Current Assets | $997.8M | - | - |
| PP&E (Net) | $63.2M | - | - |
| Goodwill | $19.3M | - | - |
| Total Assets | $1.1B | - | - |
| Current Liabilities | $127.1M | - | - |
| Total Debt | $378.4M | - | - |
| Shareholders' Equity | $577.3M | -$2.5B | - |